LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… ODD from FDA and pre-clinical data was presented at two scientific meetings. QR-313 is expected to enter the clinic … and Thaddeus (Ted) Dryja appointed to ProQR’s ScientificAdvisoryBoard (SAB). In vivo proof of concept data for novel Axiomer …